What's Happening?
Corrixr Therapeutics, a pre-clinical genetic medicine company, has announced the appointment of Nancy Whiting, PharmD, as the new Chair of its Board of Directors. This transition follows the retirement announcement of Janice E. Nevin, M.D., MPH, from
ChristianaCare, effective September 1, 2026. Dr. Nevin will continue to serve on Corrixr's board, while Jenn Schwartz will succeed her as President and CEO of ChristianaCare. Nancy Whiting, who has been the CEO of Recludix Pharma, brings extensive experience in oncology drug development and corporate strategy. Her appointment comes as Corrixr advances its lead program, CXR101, toward clinical trials. CXR101 targets NRF2, a transcription factor hyperactive in squamous cell carcinomas, using a CRISPR-based gene editing approach.
Why It's Important?
The appointment of Nancy Whiting as Board Chair is significant for Corrixr Therapeutics as it seeks to advance its innovative genetic medicine solutions for squamous cell carcinomas. Whiting's extensive background in oncology drug development and corporate strategy is expected to strengthen Corrixr's leadership at a critical juncture. Her experience with Seagen, where she contributed to the development and approval of several cancer therapies, positions her to guide Corrixr's strategic direction effectively. This leadership change is crucial as Corrixr prepares to bring its novel treatment, CXR101, to clinical trials, potentially offering a new therapeutic option for patients with treatment-resistant cancers.
What's Next?
With Nancy Whiting at the helm, Corrixr Therapeutics is poised to advance CXR101 toward an Investigational New Drug (IND) filing and first-in-human trials. The company aims to demonstrate the proof-of-mechanism for its CRISPR-based approach to targeting NRF2 in squamous cell carcinomas. As Corrixr progresses, it will likely focus on securing regulatory approvals and partnerships to support the clinical development of CXR101. The leadership transition also suggests potential strategic collaborations and investments to further Corrixr's mission of developing breakthrough treatments for challenging cancers.
